-+ 0.00%
-+ 0.00%
-+ 0.00%

PALVELLA THERAPEUTICS SUBMITS FIRST MODULE OF ROLLING NEW DRUG APPLICATION TO FDA FOR QTORIN™ RAPAMYCIN FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS

Reuters·06/29/2026 11:30:00

Please log in to view news